Home' Australian Pharmacist : Australian Pharmacist December2016 Contents Australian Pharmacist December 2016 I © Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each item. They are included for the information of PSA members.
It is up to the individual member to use their professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses nor confirms
claims made in the items. (Where provided by the company references citing evidence are included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all pharmacists and which does not reflect unfavourably
directly or by implication on the pharmacy profession or the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is the
responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does not constitute an endorsement by PSA of the claims, products
AUSTRALIA’S MOST CLOSELY READ PHARMACY JOURNAL
PRINT POST APPROVED
The evidence: Omega-3 and
-6 fatty acids, and turmeric
Old drug new indication
Propanolol for forgetting
the fear after trauma?
The quest for
Australia’s highest rated
TO ADVERTISE CONTACT
email@example.com | Jonathon Tremain 02 9988 4689 | Amanda Bennetts 0402 055 022 | Jeff Johnston 02 9871 5520
Community pharmacists value and use Australian Pharmacist for six of their top
seven information needs.
Most credible for patient counselling, S2 S3 medicines, professional services,
clinical information, prescription medicines and CPD (education).
Pharmacy Publications & Media 2016. Competitive Advantage Research, July 2016
quality of life and independence and
represents an additional burden to those
also living with the daily challenge of
diabetes. This novel, biodegradable
eye implant now provides us with an
important new option for DME.’
Ozurdex is injected into the eye (vitreous)
by an ophthalmologist, using a specifically
designed single-use applicator.
The implant is designed to provide
sustained delivery, slowly releasing a
potent corticosteroid (dexamethasone)
directly into the vitreous, potentially
resulting in less frequent injections.
An in vitro study showed that treatment
with Ozurdex can inhibit not only VEGF
but also a range of other inflammatory
mechanisms implicated in the
development of DME. In clinical trials,
Ozurdex delivered a rapid and significant
vision improvement of 15 or more letters
compared with sham treatment in DME
patients, as early as 21 days after study
It also provided
sustained, long-term improvements
in vision in DME patients with a mean
of four injections over three years,
compared with sham treatment (22.2%
patients had a ≥15-letter improvement
from baseline with OZURDEX® 700mcg
versus 12.0% with sham; P≤0.018).
1. Boyer DS, et al; Ozurdex MEAD Study Group. Three-year,
randomized, sham-controlled trial of dexamethasone intravitreal
implant in patients with diabetic macular edema. Ophthalmology.
2014 Oct;121(10):1904–14 .
Orbis Australasia, maker of DU’IT Tough
Hands, has launched DU’IT VE+ to
Australian pharmacy. Enriched with
the highest concentration of natural
vitamin E, new DU’IT VE+ provides six
times the potency of standard vitamin E
cream. Monique Char, Orbis Australasia
Marketing Manager said the Company
was excited to expand its DU’IT skincare
range and introduce DU’IT VE+ to
Australian pharmacy. ‘ The protective and
nourishing qualities of DU’IT VE+ helps
the skin to remain radiant and hydrated
around the clock. It works to neutralise
free radicals such as pollution, smoking
and air-conditioning, which most of us
are exposed to daily and can potentially
damage our skin,’ Ms Char said.
DU’IT VE+ is recommended for both
men and women aged 18–65+ with skin
Uneven skin tone / blemishes: dry
patches, red spots
Scarring: acne pock marks, burns or
Stretch marks: pregnancy, pre-& -post
natal, growth spurts and obesity
Very dry skin: dry skin associated with
After sun care: sun spots, fine line
It is also suitable as a daily facial
moisturiser applied before make-up.
On 1 November the sustained-release
eye implant Ozurdex (dexamethasone
700mcg), was listed on the
Pharmaceutical Benefits Scheme (PBS)
for patients with visual impairment
due to diabetic macular oedema
(DME) who have had cataract surgery
(pseudophakic), are scheduled to
have cataract surgery and have a
contraindication, have failed to respond
to, or are otherwise unsuitable for,
treatment with a vascular endothelial
growth factor inhibitor (anti-VEGF).
University of Sydney Ophthalmologist,
Professor Mark Gillies said: ‘Sight
impairment has a significant impact on
Links Archive Australian Pharmacist November 2016 Australian Pharmacist January 2017 Navigation Previous Page Next Page